Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD6563
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
AZD6563 is an investigational mRNA-based vaccine developed by AstraZeneca for the prevention of COVID-19. It is designed to encode the spike protein of the SARS-CoV-2 virus, specifically targeting the Omicron XBB.1.5 variant. The vaccine is part of AstraZeneca's next-generation COVID-19 vaccine portfolio, moving beyond the viral vector platform (AZD1222) into mRNA technology. It is currently being evaluated in Phase I clinical trials (such as the ARTEMIS-C study) to assess its safety and immunogenicity compared to earlier mRNA vaccine candidates like AZD9838.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on AZD6563.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD6563.